Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2002 Apr;39(4):225–242. doi: 10.1136/jmg.39.4.225

Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility

M M de Jong 1, I Nolte 1, G J te Meerman 1, W T A van der Graaf 1, J Oosterwijk 1, J Kleibeuker 1, M Schaapveld 1, E G E de Vries 1
PMCID: PMC1735082  PMID: 11950848

Full Text

The Full Text of this article is available as a PDF (302.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. C. Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. Am J Hematol. 1994 Feb;45(2):146–149. doi: 10.1002/ajh.2830450210. [DOI] [PubMed] [Google Scholar]
  2. Adélaïde J., Chaffanet M., Imbert A., Allione F., Geneix J., Popovici C., van Alewijk D., Trapman J., Zeillinger R., Børresen-Dale A. L. Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer. 1998 Jul;22(3):186–199. doi: 10.1002/(sici)1098-2264(199807)22:3<186::aid-gcc4>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  3. Agúndez J. A., Ladero J. M., Olivera M., Abildúa R., Román J. M., Benítez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology. 1995 Jan-Feb;52(1):7–11. doi: 10.1159/000227419. [DOI] [PubMed] [Google Scholar]
  4. Alexandrie A. K., Sundberg M. I., Seidegård J., Tornling G., Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994 Sep;15(9):1785–1790. doi: 10.1093/carcin/15.9.1785. [DOI] [PubMed] [Google Scholar]
  5. Allen R. D. Polymorphism of the human TNF-alpha promoter--random variation or functional diversity? Mol Immunol. 1999 Oct-Nov;36(15-16):1017–1027. doi: 10.1016/s0161-5890(99)00127-3. [DOI] [PubMed] [Google Scholar]
  6. Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Laughlin R., Nemoto T., Michalek A. M., Harrington A. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995 Aug 15;55(16):3483–3485. [PubMed] [Google Scholar]
  7. Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996 Nov 13;276(18):1494–1501. [PubMed] [Google Scholar]
  8. Anbazhagan R., Fujii H., Gabrielson E. Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol. 1998 Mar;152(3):815–819. [PMC free article] [PubMed] [Google Scholar]
  9. Andersen T. I. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol. 1996;35(4):407–410. doi: 10.3109/02841869609109913. [DOI] [PubMed] [Google Scholar]
  10. Andersen T. I., Heimdal K. R., Skrede M., Tveit K., Berg K., Børresen A. L. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet. 1994 Dec;94(6):665–670. doi: 10.1007/BF00206961. [DOI] [PubMed] [Google Scholar]
  11. Arruda V. R., Grignolli C. E., Gonçalves M. S., Soares M. C., Menezes R., Saad S. T., Costa F. F. Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Clin Genet. 1998 Sep;54(3):210–214. doi: 10.1111/j.1399-0004.1998.tb04286.x. [DOI] [PubMed] [Google Scholar]
  12. Athma P., Rappaport R., Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996 Dec;92(2):130–134. doi: 10.1016/s0165-4608(96)00328-7. [DOI] [PubMed] [Google Scholar]
  13. Badawi A. F., Hirvonen A., Bell D. A., Lang N. P., Kadlubar F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995 Nov 15;55(22):5230–5237. [PubMed] [Google Scholar]
  14. Bailey L. R., Roodi N., Dupont W. D., Parl F. F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998 Nov 15;58(22):5038–5041. [PubMed] [Google Scholar]
  15. Bailey L. R., Roodi N., Verrier C. S., Yee C. J., Dupont W. D., Parl F. F. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res. 1998 Jan 1;58(1):65–70. [PubMed] [Google Scholar]
  16. Bakkenist C. J., Koreth J., Williams C. S., Hunt N. C., McGee J. O. Heat shock cognate 70 mutations in sporadic breast carcinoma. Cancer Res. 1999 Sep 1;59(17):4219–4221. [PubMed] [Google Scholar]
  17. Barkardóttir R. B., Jóhannsson O. T., Arason A., Gudnason V., Egilsson V. Polymorphism of the c-Ha-ras-1 proto-oncogene in sporadic and familial breast cancer. Int J Cancer. 1989 Aug 15;44(2):251–255. doi: 10.1002/ijc.2910440211. [DOI] [PubMed] [Google Scholar]
  18. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196. [PubMed] [Google Scholar]
  19. Bebb D. G., Yu Z., Chen J., Telatar M., Gelmon K., Phillips N., Gatti R. A., Glickman B. W. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer. 1999 Aug;80(12):1979–1981. doi: 10.1038/sj.bjc.6690630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Beckman L. E., Van Landeghem G. F., Sikström C., Wahlin A., Markevärn B., Hallmans G., Lenner P., Athlin L., Stenling R., Beckman L. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999 Jul;20(7):1231–1233. doi: 10.1093/carcin/20.7.1231. [DOI] [PubMed] [Google Scholar]
  21. Begg L., Kuller L. H., Gutai J. P., Caggiula A. G., Wolmark N., Watson C. G. Endogenous sex hormone levels and breast cancer risk. Genet Epidemiol. 1987;4(4):233–247. doi: 10.1002/gepi.1370040402. [DOI] [PubMed] [Google Scholar]
  22. Bell D. A., Badawi A. F., Lang N. P., Ilett K. F., Kadlubar F. F., Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995 Nov 15;55(22):5226–5229. [PubMed] [Google Scholar]
  23. Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R. C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995 Aug 15;55(16):3537–3542. [PubMed] [Google Scholar]
  24. Bell D. A., Taylor J. A., Butler M. A., Stephens E. A., Wiest J., Brubaker L. H., Kadlubar F. F., Lucier G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993 Aug;14(8):1689–1692. doi: 10.1093/carcin/14.8.1689. [DOI] [PubMed] [Google Scholar]
  25. Bergman-Jungeström M., Gentile M., Lundin A. C., Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer. 1999 Aug 20;84(4):350–353. doi: 10.1002/(sici)1097-0215(19990820)84:4<350::aid-ijc3>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  26. Bernstein L., Press M. F. Does estrogen receptor expression in normal breast tissue predict breast cancer risk? J Natl Cancer Inst. 1998 Jan 7;90(1):5–7. doi: 10.1093/jnci/90.1.5. [DOI] [PubMed] [Google Scholar]
  27. Beutler B., Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol. 1989;7:625–655. doi: 10.1146/annurev.iy.07.040189.003205. [DOI] [PubMed] [Google Scholar]
  28. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170–8174. doi: 10.1073/pnas.95.14.8170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Bianco T., Chenevix-Trench G., Walsh D. C., Cooper J. E., Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000 Feb;21(2):147–151. doi: 10.1093/carcin/21.2.147. [DOI] [PubMed] [Google Scholar]
  30. Bignell G. R., Barfoot R., Seal S., Collins N., Warren W., Stratton M. R. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res. 1998 Apr 1;58(7):1384–1386. [PubMed] [Google Scholar]
  31. Biswal B. M., Kumar R., Julka P. K., Sharma U., Vaidya M. C. Human leucocytic antigens (HLA) in breast cancer. Indian J Med Sci. 1998 May;52(5):177–183. [PubMed] [Google Scholar]
  32. Boardman L. A., Thibodeau S. N., Schaid D. J., Lindor N. M., McDonnell S. K., Burgart L. J., Ahlquist D. A., Podratz K. C., Pittelkow M., Hartmann L. C. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998 Jun 1;128(11):896–899. doi: 10.7326/0003-4819-128-11-199806010-00004. [DOI] [PubMed] [Google Scholar]
  33. Bouillenne C., Deneufbourg J. M. Positive correlation between breast cancer incidence and HLA antigens. Oncology. 1979;36(4):156–159. doi: 10.1159/000225331. [DOI] [PubMed] [Google Scholar]
  34. Broeks A., Urbanus J. H., Floore A. N., Dahler E. C., Klijn J. G., Rutgers E. J., Devilee P., Russell N. S., van Leeuwen F. E., van 't Veer L. J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000 Feb;66(2):494–500. doi: 10.1086/302746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Bruskiewich R., Schertzer M., Wood S. A 2.8 megabase YAC contig spanning D8S339, which is tightly linked to the Werner syndrome locus. Genome. 1997 Feb;40(1):77–83. doi: 10.1139/g97-010. [DOI] [PubMed] [Google Scholar]
  36. Buchert E. T., Woosley R. L., Swain S. M., Oliver S. J., Coughlin S. S., Pickle L., Trock B., Riegel A. T. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics. 1993 Dec;3(6):322–327. doi: 10.1097/00008571-199312000-00006. [DOI] [PubMed] [Google Scholar]
  37. Bulovskaya L. N., Krupkin R. G., Bochina T. A., Shipkova A. A., Pavlova M. V. Acetylator phenotype in patients with breast cancer. Oncology. 1978;35(4):185–188. doi: 10.1159/000225282. [DOI] [PubMed] [Google Scholar]
  38. Bélanger A., Hum D. W., Beaulieu M., Lévesque E., Guillemette C., Tchernof A., Bélanger G., Turgeon D., Dubois S. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):301–310. doi: 10.1016/s0960-0760(97)00183-0. [DOI] [PubMed] [Google Scholar]
  39. Børresen A. L., Andersen T. I., Garber J., Barbier-Piraux N., Thorlacius S., Eyfjörd J., Ottestad L., Smith-Sørensen B., Hovig E., Malkin D. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992 Jun 1;52(11):3234–3236. [PubMed] [Google Scholar]
  40. Børresen A. L., Andersen T. I., Tretli S., Heiberg A., Møller P. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer. 1990 Nov;2(4):339–340. doi: 10.1002/gcc.2870020412. [DOI] [PubMed] [Google Scholar]
  41. Campbell I. G., Eccles D. M., Dunn B., Davis M., Leake V. p53 polymorphism in ovarian and breast cancer. Lancet. 1996 Feb 10;347(8998):393–394. doi: 10.1016/s0140-6736(96)90569-3. [DOI] [PubMed] [Google Scholar]
  42. Capon D. J., Chen E. Y., Levinson A. D., Seeburg P. H., Goeddel D. V. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature. 1983 Mar 3;302(5903):33–37. doi: 10.1038/302033a0. [DOI] [PubMed] [Google Scholar]
  43. Carey A. H., Waterworth D., Patel K., White D., Little J., Novelli P., Franks S., Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994 Oct;3(10):1873–1876. doi: 10.1093/hmg/3.10.1873. [DOI] [PubMed] [Google Scholar]
  44. Carroll B. T., Couch F. J., Rebbeck T. R., Weber B. L. Polymorphisms in PTEN in breast cancer families. J Med Genet. 1999 Feb;36(2):94–96. [PMC free article] [PubMed] [Google Scholar]
  45. Cascorbi I., Drakoulis N., Brockmöller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 Sep;57(3):581–592. [PMC free article] [PubMed] [Google Scholar]
  46. Champeme M. H., Bieche I., Latil A., Hacene K., Lidereau R. Association between restriction fragment length polymorphism of the L-myc gene and lung metastasis in human breast cancer. Int J Cancer. 1992 Jan 2;50(1):6–9. doi: 10.1002/ijc.2910500103. [DOI] [PubMed] [Google Scholar]
  47. Charrier J., Maugard C. M., Le Mevel B., Bignon Y. J. Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer. 1999 Jan;79(2):346–353. doi: 10.1038/sj.bjc.6690055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Chen J., Birkholtz G. G., Lindblom P., Rubio C., Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 1998 Apr 1;58(7):1376–1379. [PubMed] [Google Scholar]
  49. Chen J., Lindblom A. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet. 2000 May;57(5):394–397. doi: 10.1034/j.1399-0004.2000.570511.x. [DOI] [PubMed] [Google Scholar]
  50. Chen J., Lindblom P., Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet. 1998 Jan;102(1):124–125. [PubMed] [Google Scholar]
  51. Chen S. A., Besman M. J., Sparkes R. S., Zollman S., Klisak I., Mohandas T., Hall P. F., Shively J. E. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA. 1988 Jan-Feb;7(1):27–38. doi: 10.1089/dna.1988.7.27. [DOI] [PubMed] [Google Scholar]
  52. Chouchane L., Ahmed S. B., Baccouche S., Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer. 1997 Oct 15;80(8):1489–1496. doi: 10.1002/(sici)1097-0142(19971015)80:8<1489::aid-cncr17>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  53. Chuaqui R. F., Sanz-Ortega J., Vocke C., Linehan W. M., Sanz-Esponera J., Zhuang Z., Emmert-Buck M. R., Merino M. J. Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas. Cancer Res. 1995 Nov 1;55(21):4995–4998. [PubMed] [Google Scholar]
  54. Clarke A. R., Purdie C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L., Wyllie A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993 Apr 29;362(6423):849–852. doi: 10.1038/362849a0. [DOI] [PubMed] [Google Scholar]
  55. Claus E. B., Risch N., Thompson W. D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994 Feb 1;73(3):643–651. doi: 10.1002/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  56. Claus E. B. The genetic epidemiology of cancer. Cancer Surv. 1995;25:13–26. [PubMed] [Google Scholar]
  57. Coles C., Condie A., Chetty U., Steel C. M., Evans H. J., Prosser J. p53 mutations in breast cancer. Cancer Res. 1992 Oct 1;52(19):5291–5298. [PubMed] [Google Scholar]
  58. Cordon A. L., James D. C. HL-A and carcinoma of the breast. Lancet. 1973 Sep 8;2(7828):565–565. doi: 10.1016/s0140-6736(73)92384-2. [DOI] [PubMed] [Google Scholar]
  59. Corell B., Zoll B. Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast, and ovarian cancer. Hum Genet. 1988 Jul;79(3):255–259. doi: 10.1007/BF00366247. [DOI] [PubMed] [Google Scholar]
  60. Cortessis V., Ingles S., Millikan R., Diep A., Gatti R. A., Richardson L., Thompson W. D., Paganini-Hill A., Sparkes R. S., Haile R. W. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res. 1993 Nov 1;53(21):5083–5086. [PubMed] [Google Scholar]
  61. Coughlin S. S., Piper M. Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):1023–1032. [PubMed] [Google Scholar]
  62. Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6;230(4730):1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  63. Curran J. E., Vaughan T., Lea R. A., Weinstein S. R., Morrison N. A., Griffiths L. R. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999 Dec 10;83(6):723–726. doi: 10.1002/(sici)1097-0215(19991210)83:6<723::aid-ijc4>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  64. Curran J. E., Weinstein S. R., Griffiths L. R. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett. 2000 May 29;153(1-2):113–120. doi: 10.1016/s0304-3835(00)00361-x. [DOI] [PubMed] [Google Scholar]
  65. Deitz A. C., Zheng W., Leff M. A., Gross M., Wen W. Q., Doll M. A., Xiao G. H., Folsom A. R., Hein D. W. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):905–910. [PubMed] [Google Scholar]
  66. Delfino R. J., Sinha R., Smith C., West J., White E., Lin H. J., Liao S. Y., Gim J. S., Ma H. L., Butler J. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis. 2000 Apr;21(4):607–615. doi: 10.1093/carcin/21.4.607. [DOI] [PubMed] [Google Scholar]
  67. Deng G., Chen L. C., Schott D. R., Thor A., Bhargava V., Ljung B. M., Chew K., Smith H. S. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res. 1994 Jan 15;54(2):499–505. [PubMed] [Google Scholar]
  68. Dunning A. M., Healey C. S., Pharoah P. D., Foster N. A., Lipscombe J. M., Redman K. L., Easton D. F., Day N. E., Ponder B. A. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer. 1998 Jun;77(11):2045–2047. doi: 10.1038/bjc.1998.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Dunning A. M., Healey C. S., Pharoah P. D., Teare M. D., Ponder B. A., Easton D. F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):843–854. [PubMed] [Google Scholar]
  70. Dunning A. M., McBride S., Gregory J., Durocher F., Foster N. A., Healey C. S., Smith N., Pharoah P. D., Luben R. N., Easton D. F. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis. 1999 Nov;20(11):2131–2135. doi: 10.1093/carcin/20.11.2131. [DOI] [PubMed] [Google Scholar]
  71. Easton D. F. Cancer risks in A-T heterozygotes. Int J Radiat Biol. 1994 Dec;66(6 Suppl):S177–S182. doi: 10.1080/09553009414552011. [DOI] [PubMed] [Google Scholar]
  72. Easton D. F. The inherited component of cancer. Br Med Bull. 1994 Jul;50(3):527–535. doi: 10.1093/oxfordjournals.bmb.a072908. [DOI] [PubMed] [Google Scholar]
  73. Easton D. Breast cancer genes--what are the real risks? Nat Genet. 1997 Jul;16(3):210–211. doi: 10.1038/ng0797-210. [DOI] [PubMed] [Google Scholar]
  74. Emanuel B. S., Seizinger B. R. Report of the committee on the genetic constitution of chromosome 22. Cytogenet Cell Genet. 1990;55(1-4):245–253. doi: 10.1159/000133018. [DOI] [PubMed] [Google Scholar]
  75. Eng C. Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol. 1998 Mar;12(3):701–710. doi: 10.3892/ijo.12.3.701. [DOI] [PubMed] [Google Scholar]
  76. Esteller M., Corn P. G., Urena J. M., Gabrielson E., Baylin S. B., Herman J. G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998 Oct 15;58(20):4515–4518. [PubMed] [Google Scholar]
  77. Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., Dormishian F., Domingo R., Jr, Ellis M. C., Fullan A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399–408. doi: 10.1038/ng0896-399. [DOI] [PubMed] [Google Scholar]
  78. Feigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15;57(6):1063–1065. [PubMed] [Google Scholar]
  79. Feigelson H. S., Henderson B. E. Estrogens and breast cancer. Carcinogenesis. 1996 Nov;17(11):2279–2284. doi: 10.1093/carcin/17.11.2279. [DOI] [PubMed] [Google Scholar]
  80. Feigelson H. S., Shames L. S., Pike M. C., Coetzee G. A., Stanczyk F. Z., Henderson B. E. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 1998 Feb 15;58(4):585–587. [PubMed] [Google Scholar]
  81. Feilotter H. E., Coulon V., McVeigh J. L., Boag A. H., Dorion-Bonnet F., Duboué B., Latham W. C., Eng C., Mulligan L. M., Longy M. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer. 1999 Feb;79(5-6):718–723. doi: 10.1038/sj.bjc.6690115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Firgaira F. A., Seshadri R., McEvoy C. R., Dite G. S., Giles G. G., McCredie M. R., Southey M. C., Venter D. J., Hopper J. L. HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years. J Natl Cancer Inst. 1999 Dec 15;91(24):2107–2111. doi: 10.1093/jnci/91.24.2107. [DOI] [PubMed] [Google Scholar]
  83. FitzGerald M. G., Bean J. M., Hegde S. R., Unsal H., MacDonald D. J., Harkin D. P., Finkelstein D. M., Isselbacher K. J., Haber D. A. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar;15(3):307–310. doi: 10.1038/ng0397-307. [DOI] [PubMed] [Google Scholar]
  84. FitzGerald M. G., Marsh D. J., Wahrer D., Bell D., Caron S., Shannon K. E., Ishioka C., Isselbacher K. J., Garber J. E., Eng C. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998 Aug 13;17(6):727–731. doi: 10.1038/sj.onc.1201984. [DOI] [PubMed] [Google Scholar]
  85. Fontana X., Peyrottes I., Rossi C., Leblanc-Talent P., Ettore F., Namer M., Bussière F. Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu1 gene in primary breast cancers: an update with an additional 114 cases. Mutat Res. 1998 Jul 17;403(1-2):45–53. doi: 10.1016/s0027-5107(98)00025-6. [DOI] [PubMed] [Google Scholar]
  86. Ford D., Easton D. F. The genetics of breast and ovarian cancer. Br J Cancer. 1995 Oct;72(4):805–812. doi: 10.1038/bjc.1995.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Franke S., Klawitz I., Schnakenberg E., Rommel B., Van de Ven W., Bullerdiek J., Schloot W. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem Biophys Res Commun. 1994 Feb 28;199(1):52–55. doi: 10.1006/bbrc.1994.1192. [DOI] [PubMed] [Google Scholar]
  88. Freihoff D., Kempe A., Beste B., Wappenschmidt B., Kreyer E., Hayashi Y., Meindl A., Krebs D., Wiestler O. D., von Deimling A. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 1999 Feb;79(5-6):754–758. doi: 10.1038/sj.bjc.6690121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Furuuchi K., Tada M., Yamada H., Kataoka A., Furuuchi N., Hamada J., Takahashi M., Todo S., Moriuchi T. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000 Jun;156(6):1997–2005. doi: 10.1016/s0002-9440(10)65072-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Garber J. E., Goldstein A. M., Kantor A. F., Dreyfus M. G., Fraumeni J. F., Jr, Li F. P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991 Nov 15;51(22):6094–6097. [PubMed] [Google Scholar]
  91. Garcia-Merino A., Alper C. A., Usuku K., Marcus-Bagley D., Lincoln R., Awdeh Z., Yunis E. J., Eisenbarth G. S., Brink S. J., Hauser S. L. Tumor necrosis factor (TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex and TNF secretion. Hum Immunol. 1996 Sep 15;50(1):11–21. doi: 10.1016/0198-8859(96)00064-x. [DOI] [PubMed] [Google Scholar]
  92. García-Closas M., Kelsey K. T., Hankinson S. E., Spiegelman D., Springer K., Willett W. C., Speizer F. E., Hunter D. J. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst. 1999 Nov 17;91(22):1960–1964. doi: 10.1093/jnci/91.22.1960. [DOI] [PubMed] [Google Scholar]
  93. Garrett P. A., Hulka B. S., Kim Y. L., Farber R. A. HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):131–138. [PubMed] [Google Scholar]
  94. Gatti R. A., Sparkes R. S., Field L. L., Spence M. A., Harris N. S., Freidin M. Genetic linkage analysis in a high-risk cancer family: HLA and 24 other markers. Cancer Genet Cytogenet. 1983 Jan;8(1):9–18. doi: 10.1016/0165-4608(83)90061-4. [DOI] [PubMed] [Google Scholar]
  95. Gatti R. A., Tward A., Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999 Dec;68(4):419–423. doi: 10.1006/mgme.1999.2942. [DOI] [PubMed] [Google Scholar]
  96. Gerbault-Seureau M., Vielh P., Dutrillaux B. Recurrent HSR in the centromeric region of chromosome 8 in breast cancer. Ann Genet. 1987;30(3):146–151. [PubMed] [Google Scholar]
  97. Gershoni-Baruch R., Patael Y., Dagan, Figer A., Kasinetz L., Kadouri E., Bruchim Bar Sade R., Friedman E. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Br J Cancer. 2000 Jul;83(2):153–155. doi: 10.1054/bjoc.2000.1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Giardiello F. M., Welsh S. B., Hamilton S. R., Offerhaus G. J., Gittelsohn A. M., Booker S. V., Krush A. J., Yardley J. H., Luk G. D. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987 Jun 11;316(24):1511–1514. doi: 10.1056/NEJM198706113162404. [DOI] [PubMed] [Google Scholar]
  99. Goldfarb M., Shimizu K., Perucho M., Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature. 1982 Apr 1;296(5856):404–409. doi: 10.1038/296404a0. [DOI] [PubMed] [Google Scholar]
  100. Gosse-Brun S., Sauvaigo S., Daver A., Page M., Lortholary A., Larra F., Bignon Y. J., Bernard-Gallon D. Specific H-Ras minisatellite alleles in breast cancer susceptibility. Anticancer Res. 1999 Nov-Dec;19(6B):5191–5196. [PubMed] [Google Scholar]
  101. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  102. Greene M. H. Genetics of breast cancer. Mayo Clin Proc. 1997 Jan;72(1):54–65. doi: 10.4065/72.1.54. [DOI] [PubMed] [Google Scholar]
  103. Grimmond S. M., Palmer J. M., Walters M. K., Scott C., Nancarrow D. J., Teh B. T., Elmes C., Pyke C., Khoo S. K., Bennett I. Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families. Hum Genet. 1996 Jul;98(1):80–85. doi: 10.1007/s004390050164. [DOI] [PubMed] [Google Scholar]
  104. Grossman M. H., Emanuel B. S., Budarf M. L. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2. Genomics. 1992 Apr;12(4):822–825. doi: 10.1016/0888-7543(92)90316-k. [DOI] [PubMed] [Google Scholar]
  105. Guillemette C., De Vivo I., Hankinson S. E., Haiman C. A., Spiegelman D., Housman D. E., Hunter D. J. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):711–714. [PubMed] [Google Scholar]
  106. Guillemette C., Millikan R. C., Newman B., Housman D. E. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 2000 Feb 15;60(4):950–956. [PubMed] [Google Scholar]
  107. Guldberg H. C., Marsden C. A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975 Jun;27(2):135–206. [PubMed] [Google Scholar]
  108. Haiman C. A., Hankinson S. E., Spiegelman D., Colditz G. A., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 1999 Mar 1;59(5):1015–1020. [PubMed] [Google Scholar]
  109. Haiman C. A., Hankinson S. E., Spiegelman D., De Vivo I., Colditz G. A., Willett W. C., Speizer F. E., Hunter D. J. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 2000 Jul 15;87(2):204–210. [PubMed] [Google Scholar]
  110. Hall J. M., Huey B., Morrow J., Newman B., Lee M., Jones E., Carter C., Buehring G. C., King M. C. Rare HRAS alleles and susceptibility to human breast cancer. Genomics. 1990 Jan;6(1):188–191. doi: 10.1016/0888-7543(90)90466-8. [DOI] [PubMed] [Google Scholar]
  111. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., King M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990 Dec 21;250(4988):1684–1689. doi: 10.1126/science.2270482. [DOI] [PubMed] [Google Scholar]
  112. Hanna I. H., Dawling S., Roodi N., Guengerich F. P., Parl F. F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 2000 Jul 1;60(13):3440–3444. [PubMed] [Google Scholar]
  113. Harries L. W., Stubbins M. J., Forman D., Howard G. C., Wolf C. R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997 Apr;18(4):641–644. doi: 10.1093/carcin/18.4.641. [DOI] [PubMed] [Google Scholar]
  114. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  115. Hayashi S., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem. 1991 Sep;110(3):407–411. doi: 10.1093/oxfordjournals.jbchem.a123594. [DOI] [PubMed] [Google Scholar]
  116. Hayes J. D., Pulford D. J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30(6):445–600. doi: 10.3109/10409239509083491. [DOI] [PubMed] [Google Scholar]
  117. Healey C. S., Dunning A. M., Durocher F., Teare D., Pharoah P. D., Luben R. N., Easton D. F., Ponder B. A. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis. 2000 Feb;21(2):189–193. doi: 10.1093/carcin/21.2.189. [DOI] [PubMed] [Google Scholar]
  118. Heim S., Mitelman F. Nineteen of 26 cellular oncogenes precisely localized in the human genome map to one of the 83 bands involved in primary cancer-specific rearrangements. Hum Genet. 1987 Jan;75(1):70–72. doi: 10.1007/BF00273843. [DOI] [PubMed] [Google Scholar]
  119. Hein D. W., Doll M. A., Rustan T. D., Ferguson R. J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 1995 Aug 15;55(16):3531–3536. [PubMed] [Google Scholar]
  120. Helzlsouer K. J., Huang H. Y., Strickland P. T., Hoffman S., Alberg A. J., Comstock G. W., Bell D. A. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):945–949. [PubMed] [Google Scholar]
  121. Helzlsouer K. J., Selmin O., Huang H. Y., Strickland P. T., Hoffman S., Alberg A. J., Watson M., Comstock G. W., Bell D. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst. 1998 Apr 1;90(7):512–518. doi: 10.1093/jnci/90.7.512. [DOI] [PubMed] [Google Scholar]
  122. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Höglund P. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998 Jan 8;391(6663):184–187. doi: 10.1038/34432. [DOI] [PubMed] [Google Scholar]
  123. Henderson B. E., Feigelson H. S. Hormonal carcinogenesis. Carcinogenesis. 2000 Mar;21(3):427–433. doi: 10.1093/carcin/21.3.427. [DOI] [PubMed] [Google Scholar]
  124. Hill S. M., Fuqua S. A., Chamness G. C., Greene G. L., McGuire W. L. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 1;49(1):145–148. [PubMed] [Google Scholar]
  125. Ho K. Y., Kalle W. H., Lo T. H., Lam W. Y., Tang C. M. Reduced expression of APC and DCC gene protein in breast cancer. Histopathology. 1999 Sep;35(3):249–256. doi: 10.1046/j.1365-2559.1999.00725.x. [DOI] [PubMed] [Google Scholar]
  126. Honda K., Ishizaki K., Ikenaga M., Toguchida J., Inamoto T., Tanaka K., Ozawa K. Increased frequency of specific alleles of the c-Ha-ras gene in Japanese cancer patients. Hum Genet. 1988 Aug;79(4):297–300. doi: 10.1007/BF00282164. [DOI] [PubMed] [Google Scholar]
  127. Hoskins K. F., Stopfer J. E., Calzone K. A., Merajver S. D., Rebbeck T. R., Garber J. E., Weber B. L. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995 Feb 15;273(7):577–585. [PubMed] [Google Scholar]
  128. Huang C. S., Chern H. D., Chang K. J., Cheng C. W., Hsu S. M., Shen C. Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999 Oct 1;59(19):4870–4875. [PubMed] [Google Scholar]
  129. Huang C. S., Chern H. D., Shen C. Y., Hsu S. M., Chang K. J. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int J Cancer. 1999 Jul 19;82(2):175–179. doi: 10.1002/(sici)1097-0215(19990719)82:2<175::aid-ijc4>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  130. Huang C. S., Shen C. Y., Chang K. J., Hsu S. M., Chern H. D. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer. 1999 Aug;80(11):1838–1843. doi: 10.1038/sj.bjc.6690608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Huerre C., Uzan G., Grzeschik K. H., Weil D., Levin M., Hors-Cayla M. C., Boué J., Kahn A., Junien C. The structural gene for transferrin (TF) maps to 3q21----3qter. Ann Genet. 1984;27(1):5–10. [PubMed] [Google Scholar]
  132. Hughes N. C., Janezic S. A., McQueen K. L., Jewett M. A., Castranio T., Bell D. A., Grant D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics. 1998 Feb;8(1):55–66. doi: 10.1097/00008571-199802000-00008. [DOI] [PubMed] [Google Scholar]
  133. Hulka B. S. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res. 1997;396:17–29. [PubMed] [Google Scholar]
  134. Hunter D. J., Hankinson S. E., Hough H., Gertig D. M., Garcia-Closas M., Spiegelman D., Manson J. E., Colditz G. A., Willett W. C., Speizer F. E. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis. 1997 Nov;18(11):2127–2132. doi: 10.1093/carcin/18.11.2127. [DOI] [PubMed] [Google Scholar]
  135. Huober J., Bertram B., Petru E., Kaufmann M., Schmähl D. Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Res Treat. 1991 Mar;18(1):43–48. doi: 10.1007/BF01975442. [DOI] [PubMed] [Google Scholar]
  136. Ilett K. F., Detchon P., Ingram D. M., Castleden W. M. Acetylation phenotype is not associated with breast cancer. Cancer Res. 1990 Oct 15;50(20):6649–6651. [PubMed] [Google Scholar]
  137. Ingles S. A., Garcia D. G., Wang W., Nieters A., Henderson B. E., Kolonel L. N., Haile R. W., Coetzee G. A. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control. 2000 Jan;11(1):25–30. doi: 10.1023/a:1008979417618. [DOI] [PubMed] [Google Scholar]
  138. Ishibe N., Hankinson S. E., Colditz G. A., Spiegelman D., Willett W. C., Speizer F. E., Kelsey K. T., Hunter D. J. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 1998 Feb 15;58(4):667–671. [PubMed] [Google Scholar]
  139. Ishizaki K., Kato M., Ikenaga M., Honda K., Ozawa K., Toguchida J. Correlation of L-myc genotypes to metastasis of gastric cancer and breast cancer. J Natl Cancer Inst. 1990 Feb 7;82(3):238–239. doi: 10.1093/jnci/82.3.238. [DOI] [PubMed] [Google Scholar]
  140. Iwase H., Greenman J. M., Barnes D. M., Hodgson S., Bobrow L., Mathew C. G. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett. 1996 Nov 29;108(2):179–184. doi: 10.1016/s0304-3835(96)04406-0. [DOI] [PubMed] [Google Scholar]
  141. Izatt L., Greenman J., Hodgson S., Ellis D., Watts S., Scott G., Jacobs C., Liebmann R., Zvelebil M. J., Mathew C. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999 Dec;26(4):286–294. [PubMed] [Google Scholar]
  142. Jaiswal A. K., Gonzalez F. J., Nebert D. W. Human dioxin-inducible cytochrome P1-450: complementary DNA and amino acid sequence. Science. 1985 Apr 5;228(4695):80–83. doi: 10.1126/science.3838385. [DOI] [PubMed] [Google Scholar]
  143. Janin N., Andrieu N., Ossian K., Laugé A., Croquette M. F., Griscelli C., Debré M., Bressac-de-Paillerets B., Aurias A., Stoppa-Lyonnet D. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer. 1999 Jun;80(7):1042–1045. doi: 10.1038/sj.bjc.6690460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Jenne D. E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Müller O., Back W., Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998 Jan;18(1):38–43. doi: 10.1038/ng0198-38. [DOI] [PubMed] [Google Scholar]
  145. Johnson D. W., Qumsiyeh M., Benkhalifa M., Marchuk D. A. Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively. Genomics. 1995 Jul 20;28(2):356–357. doi: 10.1006/geno.1995.1157. [DOI] [PubMed] [Google Scholar]
  146. Jones P. A., Laird P. W. Cancer epigenetics comes of age. Nat Genet. 1999 Feb;21(2):163–167. doi: 10.1038/5947. [DOI] [PubMed] [Google Scholar]
  147. Karnik P. S., Kulkarni S., Liu X. P., Budd G. T., Bukowski R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994 Jan 15;54(2):349–353. [PubMed] [Google Scholar]
  148. Kasid A., Lippman M. E. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem. 1987;27(1-3):465–470. doi: 10.1016/0022-4731(87)90341-4. [DOI] [PubMed] [Google Scholar]
  149. Kasperczyk A., DiMartino N. A., Krontiris T. G. Minisatellite allele diversification: the origin of rare alleles at the HRAS1 locus. Am J Hum Genet. 1990 Nov;47(5):854–859. [PMC free article] [PubMed] [Google Scholar]
  150. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993 Jun;14(6):1085–1089. doi: 10.1093/carcin/14.6.1085. [DOI] [PubMed] [Google Scholar]
  151. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993 Feb;14(1):77–87. doi: 10.1016/1040-8428(93)90007-q. [DOI] [PubMed] [Google Scholar]
  152. Kelsey J. L., Gammon M. D., John E. M. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36–47. doi: 10.1093/oxfordjournals.epirev.a036115. [DOI] [PubMed] [Google Scholar]
  153. Kelsey K. T., Hankinson S. E., Colditz G. A., Springer K., Garcia-Closas M., Spiegelman D., Manson J. E., Garland M., Stampfer M. J., Willett W. C. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):511–515. [PubMed] [Google Scholar]
  154. Kerangueven F., Essioux L., Dib A., Noguchi T., Allione F., Geneix J., Longy M., Lidereau R., Eisinger F., Pébusque M. J. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene. 1995 Mar 2;10(5):1023–1026. [PubMed] [Google Scholar]
  155. Kerangueven F., Noguchi T., Coulier F., Allione F., Wargniez V., Simony-Lafontaine J., Longy M., Jacquemier J., Sobol H., Eisinger F. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res. 1997 Dec 15;57(24):5469–5474. [PubMed] [Google Scholar]
  156. Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res. 1988 Dec;202(2):343–361. doi: 10.1016/0027-5107(88)90197-2. [DOI] [PubMed] [Google Scholar]
  157. Khaliq S., Hameed A., Khaliq T., Ayub Q., Qamar R., Mohyuddin A., Mazhar K., Qasim-Mehdi S. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 2000;4(1):23–29. doi: 10.1089/109065700316435. [DOI] [PubMed] [Google Scholar]
  158. Kiss I., Sándor J., Pajkos G., Bogner B., Hegedüs G., Ember I. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res. 2000 Jan-Feb;20(1B):519–522. [PubMed] [Google Scholar]
  159. Knudson A. G., Jr, Hethcote H. W., Brown B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5116–5120. doi: 10.1073/pnas.72.12.5116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Kristensen V. N., Andersen T. I., Lindblom A., Erikstein B., Magnus P., Børresen-Dale A. L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics. 1998 Feb;8(1):43–48. doi: 10.1097/00008571-199802000-00006. [DOI] [PubMed] [Google Scholar]
  161. Kristensen V. N., Borresen-Dale A. L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res. 2000 Apr;462(2-3):323–333. doi: 10.1016/s1383-5742(00)00018-1. [DOI] [PubMed] [Google Scholar]
  162. Krontiris T. G. Detection of cancer predisposition by hypervariable region analysis. Birth Defects Orig Artic Ser. 1990;26(1):129–140. [PubMed] [Google Scholar]
  163. Krontiris T. G., Devlin B., Karp D. D., Robert N. J., Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med. 1993 Aug 19;329(8):517–523. doi: 10.1056/NEJM199308193290801. [DOI] [PubMed] [Google Scholar]
  164. Kuligina E. S., Togo A. V., Suspitsin E. N., Grigoriev M. Y., Pozharisskiy K. M., Chagunava O. L., Berstein L. M., Theillet C., Hanson K. P., Imyanitov E. N. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett. 2000 Aug 1;156(1):45–50. doi: 10.1016/s0304-3835(00)00436-5. [DOI] [PubMed] [Google Scholar]
  165. Lachman H. M., Papolos D. F., Saito T., Yu Y. M., Szumlanski C. L., Weinshilboum R. M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 Jun;6(3):243–250. doi: 10.1097/00008571-199606000-00007. [DOI] [PubMed] [Google Scholar]
  166. Ladero J. M., Benítez J., Jara C., Llerena A., Valdivielso M. J., Muñoz J. J., Vargas E. Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology. 1991;48(2):107–110. doi: 10.1159/000226906. [DOI] [PubMed] [Google Scholar]
  167. Ladero J. M., Fernández M. J., Palmeiro R., Muñoz J. J., Jara C., Lázaro C., Pérez-Manga G. Hepatic acetylator polymorphism in breast cancer patients. Oncology. 1987;44(6):341–344. doi: 10.1159/000226508. [DOI] [PubMed] [Google Scholar]
  168. Ladona M. G., Abildúa R. E., Ladero J. M., Román J. M., Plaza M. A., Agúndez J. A., Muñoz J. J., Benítez J. CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett. 1996 Jan 19;99(1):23–28. doi: 10.1016/0304-3835(95)04033-1. [DOI] [PubMed] [Google Scholar]
  169. Lancaster J. M., Berchuck A., Carney M. E., Wiseman R., Taylor J. A. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer. 1998 Jul;78(2):277–277. doi: 10.1038/bjc.1998.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Lapidus R. G., Ferguson A. T., Ottaviano Y. L., Parl F. F., Smith H. S., Weitzman S. A., Baylin S. B., Issa J. P., Davidson N. E. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res. 1996 May;2(5):805–810. [PubMed] [Google Scholar]
  171. Larsen M. C., Angus W. G., Brake P. B., Eltom S. E., Sukow K. A., Jefcoate C. R. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res. 1998 Jun 1;58(11):2366–2374. [PubMed] [Google Scholar]
  172. Laugé A., Lefebvre C., Laurent-Puig P., Caux V., Gad S., Eng C., Longy M., Stoppa-Lyonnet D. No evidence for germline PTEN mutations in families with breast and brain tumours. Int J Cancer. 1999 Jun 21;84(3):216–219. doi: 10.1002/(sici)1097-0215(19990621)84:3<216::aid-ijc3>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  173. Lavigne J. A., Helzlsouer K. J., Huang H. Y., Strickland P. T., Bell D. A., Selmin O., Watson M. A., Hoffman S., Comstock G. W., Yager J. D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 1997 Dec 15;57(24):5493–5497. [PubMed] [Google Scholar]
  174. Lavin M. F., Concannon P., Gatti R. A. Eighth International Workshop on Ataxia-Telangiectasia (ATW8). Cancer Res. 1999 Aug 1;59(15):3845–3849. [PubMed] [Google Scholar]
  175. Lazzaro G., Agadir A., Qing W., Poria M., Mehta R. R., Moriarty R. M., Das Gupta T. K., Zhang X. K., Mehta R. G. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer. 2000 Apr;36(6):780–786. doi: 10.1016/s0959-8049(00)00016-2. [DOI] [PubMed] [Google Scholar]
  176. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  177. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  178. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  179. Lidereau R., Escot C., Theillet C., Champeme M. H., Brunet M., Gest J., Callahan R. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst. 1986 Sep;77(3):697–701. doi: 10.1093/jnci/77.3.697. [DOI] [PubMed] [Google Scholar]
  180. Liehr J. G., Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med. 1990;8(4):415–423. doi: 10.1016/0891-5849(90)90108-u. [DOI] [PubMed] [Google Scholar]
  181. Ligtenberg M. J., Hogervorst F. B., Willems H. W., Arts P. J., Brink G., Hageman S., Bosgoed E. A., Van der Looij E., Rookus M. A., Devilee P. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar;79(9-10):1475–1478. doi: 10.1038/sj.bjc.6690235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Lin H. J., Han C. Y., Bernstein D. A., Hsiao W., Lin B. K., Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 1994 May;15(5):1077–1081. doi: 10.1093/carcin/15.5.1077. [DOI] [PubMed] [Google Scholar]
  183. Lin H. J., Han C. Y., Lin B. K., Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet. 1993 Apr;52(4):827–834. [PMC free article] [PubMed] [Google Scholar]
  184. Lobaccaro J. M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., Lesimple T., Heron J. F., Pujol H., Sultan C. Male breast cancer and the androgen receptor gene. Nat Genet. 1993 Oct;5(2):109–110. doi: 10.1038/ng1093-109. [DOI] [PubMed] [Google Scholar]
  185. Lundin A. C., Söderkvist P., Eriksson B., Bergman-Jungeström M., Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res. 1999 May 15;59(10):2332–2334. [PubMed] [Google Scholar]
  186. Mackay J., Elder P. A., Porteous D. J., Steel C. M., Hawkins R. A., Going J. J., Chetty U. Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor level. Br J Cancer. 1988 Dec;58(6):710–714. doi: 10.1038/bjc.1988.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Mackenzie P. I., Owens I. S., Burchell B., Bock K. W., Bairoch A., Bélanger A., Fournel-Gigleux S., Green M., Hum D. W., Iyanagi T. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 1997 Aug;7(4):255–269. doi: 10.1097/00008571-199708000-00001. [DOI] [PubMed] [Google Scholar]
  188. Maestri I., Castagnoli A., Bertusi M., Zandi G., Vettorello G., Del Senno L. RFLPs of the Ha-ras1 protooncogene in subjects with colon-rectal carcinomas. Boll Soc Ital Biol Sper. 1987 Apr 30;63(4):305–310. [PubMed] [Google Scholar]
  189. Malkin D. Germline p53 mutations and heritable cancer. Annu Rev Genet. 1994;28:443–465. doi: 10.1146/annurev.ge.28.120194.002303. [DOI] [PubMed] [Google Scholar]
  190. Mannermaa A., Peltoketo H., Winqvist R., Ponder B. A., Kiviniemi H., Easton D. F., Poutanen M., Isomaa V., Vihko R. Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet. 1994 Mar;93(3):319–324. doi: 10.1007/BF00212030. [DOI] [PubMed] [Google Scholar]
  191. Manolitsas T. P., Englefield P., Eccles D. M., Campbell I. G. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer. 1997;75(9):1398–1399. doi: 10.1038/bjc.1997.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Marsh D. J., Coulon V., Lunetta K. L., Rocca-Serra P., Dahia P. L., Zheng Z., Liaw D., Caron S., Duboué B., Lin A. Y. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998 Mar;7(3):507–515. doi: 10.1093/hmg/7.3.507. [DOI] [PubMed] [Google Scholar]
  193. Marsh D. J., Kum J. B., Lunetta K. L., Bennett M. J., Gorlin R. J., Ahmed S. F., Bodurtha J., Crowe C., Curtis M. A., Dasouki M. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999 Aug;8(8):1461–1472. doi: 10.1093/hmg/8.8.1461. [DOI] [PubMed] [Google Scholar]
  194. Martin A. M., Weber B. L. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000 Jul 19;92(14):1126–1135. doi: 10.1093/jnci/92.14.1126. [DOI] [PubMed] [Google Scholar]
  195. Martz E., Benacerraf B. Lack of association between carcinoma of the breast and HL-A specificities. Tissue Antigens. 1973;3(1):30–38. doi: 10.1111/j.1399-0039.1973.tb00975.x. [DOI] [PubMed] [Google Scholar]
  196. Maugard C. M., Charrier J., Bignon Y. J. Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility. Chem Biol Interact. 1998 Apr 24;111-112:365–375. doi: 10.1016/s0009-2797(97)00173-7. [DOI] [PubMed] [Google Scholar]
  197. Mavridou D., Gornall R., Campbell I. G., Eccles D. M. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer. 1998 Feb;77(4):676–677. doi: 10.1038/bjc.1998.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. McBride O. W., Merry D., Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A. 1986 Jan;83(1):130–134. doi: 10.1073/pnas.83.1.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. McGuire W. L., Chamness G. C., Fuqua S. A. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov;5(11):1571–1577. doi: 10.1210/mend-5-11-1571. [DOI] [PubMed] [Google Scholar]
  200. Menasce L. P., White G. R., Harrison C. J., Boyle J. M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics. 1993 Jul;17(1):263–265. doi: 10.1006/geno.1993.1320. [DOI] [PubMed] [Google Scholar]
  201. Meyn M. S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet. 1999 May;55(5):289–304. doi: 10.1034/j.1399-0004.1999.550501.x. [DOI] [PubMed] [Google Scholar]
  202. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  203. Millikan R. C., Pittman G. S., Newman B., Tse C. K., Selmin O., Rockhill B., Savitz D., Moorman P. G., Bell D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):371–378. [PubMed] [Google Scholar]
  204. Millikan R. C., Pittman G. S., Tse C. K., Duell E., Newman B., Savitz D., Moorman P. G., Boissy R. J., Bell D. A. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis. 1998 Nov;19(11):1943–1947. doi: 10.1093/carcin/19.11.1943. [DOI] [PubMed] [Google Scholar]
  205. Mitrunen K., Jourenkova N., Kataja V., Eskelinen M., Kosma V. M., Benhamou S., Vainio H., Uusitupa M., Hirvonen A. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1343–1348. [PubMed] [Google Scholar]
  206. Morrell D., Chase C. L., Swift M. Cancers in 44 families with ataxia-telangiectasia. Cancer Genet Cytogenet. 1990 Nov 1;50(1):119–123. doi: 10.1016/0165-4608(90)90245-6. [DOI] [PubMed] [Google Scholar]
  207. Moysich K. B., Freudenheim J. L., Baker J. A., Ambrosone C. B., Bowman E. D., Schisterman E. F., Vena J. E., Shields P. G. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog. 2000 Jan;27(1):2–9. doi: 10.1002/(sici)1098-2744(200001)27:1<2::aid-mc2>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  208. Moysich K. B., Shields P. G., Freudenheim J. L., Schisterman E. F., Vena J. E., Kostyniak P., Greizerstein H., Marshall J. R., Graham S., Ambrosone C. B. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):41–44. [PubMed] [Google Scholar]
  209. Nayak B. K., Das B. R. Mutation and methylation status of p53 gene promoter in human breast tumours. Tumour Biol. 1999 Nov-Dec;20(6):341–346. doi: 10.1159/000030098. [DOI] [PubMed] [Google Scholar]
  210. Nebert D. W. Role of genetics and drug metabolism in human cancer risk. Mutat Res. 1991 Apr;247(2):267–281. doi: 10.1016/0027-5107(91)90022-g. [DOI] [PubMed] [Google Scholar]
  211. Nedelcheva Kristensen V., Andersen T. I., Erikstein B., Geitvik G., Skovlund E., Nesland J. M., Børresen-Dale A. L. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics. 1998 Oct;8(5):441–447. doi: 10.1097/00008571-199810000-00009. [DOI] [PubMed] [Google Scholar]
  212. Nedelcheva Kristensen V., Haraldsen E. K., Anderson K. B., Lønning P. E., Erikstein B., Kåresen R., Gabrielsen O. S., Børresen-Dale A. L. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999 Jun 15;59(12):2825–2828. [PubMed] [Google Scholar]
  213. Nelson H. H., Wiencke J. K., Christiani D. C., Cheng T. J., Zuo Z. F., Schwartz B. S., Lee B. K., Spitz M. R., Wang M., Xu X. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis. 1995 May;16(5):1243–1245. doi: 10.1093/carcin/16.5.1243. [DOI] [PubMed] [Google Scholar]
  214. Nelson R. L., Davis F. G., Persky V., Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer. 1995 Sep 1;76(5):875–879. doi: 10.1002/1097-0142(19950901)76:5<875::aid-cncr2820760523>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  215. Olaisen B., Teisberg P., Gedde-Dahl T., Jr The locus for apolipoprotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man. Hum Genet. 1982;62(3):233–236. doi: 10.1007/BF00333526. [DOI] [PubMed] [Google Scholar]
  216. Osborne R. J., Merlo G. R., Mitsudomi T., Venesio T., Liscia D. S., Cappa A. P., Chiba I., Takahashi T., Nau M. M., Callahan R. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 1991 Nov 15;51(22):6194–6198. [PubMed] [Google Scholar]
  217. Paradiso A., Vetrugno M. G., Capuano G., Longo S., Sibilano L., Schittulli F., Correale M., Barletta A., Pelagio G., De Lena M. Expression of GST-mu transferase in breast cancer patients and healthy controls. Int J Biol Markers. 1994 Oct-Dec;9(4):219–223. doi: 10.1177/172460089400900403. [DOI] [PubMed] [Google Scholar]
  218. Park S. K., Yoo K. Y., Lee S. J., Kim S. U., Ahn S. H., Noh D. Y., Choe K. J., Strickland P. T., Hirvonen A., Kang D. Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics. 2000 Jun;10(4):301–309. doi: 10.1097/00008571-200006000-00004. [DOI] [PubMed] [Google Scholar]
  219. Parkin D. M. Epidemiology of cancer: global patterns and trends. Toxicol Lett. 1998 Dec 28;102-103:227–234. doi: 10.1016/s0378-4274(98)00311-7. [DOI] [PubMed] [Google Scholar]
  220. Pasche B., Kolachana P., Nafa K., Satagopan J., Chen Y. G., Lo R. S., Brener D., Yang D., Kirstein L., Oddoux C. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res. 1999 Nov 15;59(22):5678–5682. [PubMed] [Google Scholar]
  221. Patel U. A., Perry M., Crane-Robinson C. Screening for germline mutations of the p53 gene in familial breast cancer patients. Eur J Clin Invest. 1995 Feb;25(2):132–137. doi: 10.1111/j.1365-2362.1995.tb01538.x. [DOI] [PubMed] [Google Scholar]
  222. Pearson W. R., Vorachek W. R., Xu S. J., Berger R., Hart I., Vannais D., Patterson D. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet. 1993 Jul;53(1):220–233. [PMC free article] [PubMed] [Google Scholar]
  223. Peller S., Kopilova Y., Slutzki S., Halevy A., Kvitko K., Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995 Dec;14(12):983–990. doi: 10.1089/dna.1995.14.983. [DOI] [PubMed] [Google Scholar]
  224. Peltoketo H., Piao Y., Mannermaa A., Ponder B. A., Isomaa V., Poutanen M., Winqvist R., Vihko R. A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro. Genomics. 1994 Sep 1;23(1):250–252. doi: 10.1006/geno.1994.1487. [DOI] [PubMed] [Google Scholar]
  225. Pemble S., Schroeder K. R., Spencer S. R., Meyer D. J., Hallier E., Bolt H. M., Ketterer B., Taylor J. B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J. 1994 May 15;300(Pt 1):271–276. doi: 10.1042/bj3000271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Perdue S. T., Terasaki P. I., Mickey M. R. HLA frequencies in cancer: a third study. IARC Sci Publ. 1978;(20):263–269. [PubMed] [Google Scholar]
  227. Perren A., Weng L. P., Boag A. H., Ziebold U., Thakore K., Dahia P. L., Komminoth P., Lees J. A., Mulligan L. M., Mutter G. L. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999 Oct;155(4):1253–1260. doi: 10.1016/S0002-9440(10)65227-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  228. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  229. Philip P. A., Rogers H. J., Millis R. R., Rubens R. D., Cartwright R. A. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1701–1706. doi: 10.1016/0277-5379(87)90453-6. [DOI] [PubMed] [Google Scholar]
  230. Pippard E. C., Hall A. J., Barker D. J., Bridges B. A. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 1988 May 15;48(10):2929–2932. [PubMed] [Google Scholar]
  231. Pistillo M. P., Nicolò G., Salvi S., Capanni P., Perdelli L., Pasciucco G., Ferrara G. B. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000 Apr;61(4):397–407. doi: 10.1016/s0198-8859(99)00179-2. [DOI] [PubMed] [Google Scholar]
  232. Polymeropoulos M. H., Xiao H., Rath D. S., Merril C. R. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res. 1991 Jan 11;19(1):195–195. doi: 10.1093/nar/19.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  233. Pontin J. E., Hamed H., Fentiman I. S., Idle J. R. Cytochrome P450dbl phenotypes in malignant and benign breast disease. Eur J Cancer. 1990;26(7):790–792. doi: 10.1016/0277-5379(90)90153-k. [DOI] [PubMed] [Google Scholar]
  234. Probst-Hensch N. M., Ingles S. A., Diep A. T., Haile R. W., Stanczyk F. Z., Kolonel L. N., Henderson B. E. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999 Jun;6(2):165–173. doi: 10.1677/erc.0.0060165. [DOI] [PubMed] [Google Scholar]
  235. Prosser J., Elder P. A., Condie A., MacFadyen I., Steel C. M., Evans H. J. Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer. 1991 Feb;63(2):181–184. doi: 10.1038/bjc.1991.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  236. Prosser J., Porter D., Coles C., Condie A., Thompson A. M., Chetty U., Steel C. M., Evans H. J. Constitutional p53 mutation in a non-Li-Fraumeni cancer family. Br J Cancer. 1992 Apr;65(4):527–528. doi: 10.1038/bjc.1992.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Rebbeck T. R., Couch F. J., Kant J., Calzone K., DeShano M., Peng Y., Chen K., Garber J. E., Weber B. L. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet. 1996 Sep;59(3):547–553. [PMC free article] [PubMed] [Google Scholar]
  238. Rebbeck T. R. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer. 1999 Dec 1;86(11 Suppl):2493–2501. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2493::aid-cncr6>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  239. Rebbeck T. R., Kantoff P. W., Krithivas K., Neuhausen S., Blackwood M. A., Godwin A. K., Daly M. B., Narod S. A., Garber J. E., Lynch H. T. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999 May;64(5):1371–1377. doi: 10.1086/302366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  240. Rebbeck T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):733–743. [PubMed] [Google Scholar]
  241. Rebbeck T. R., Rosvold E. A., Duggan D. J., Zhang J., Buetow K. H. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):511–514. [PubMed] [Google Scholar]
  242. Rebbeck T. R., Walker A. H., Phelan C. M., Godwin A. K., Buetow K. H., Garber J. E., Narod S. A., Weber B. L. Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Prog Clin Biol Res. 1997;396:53–61. [PubMed] [Google Scholar]
  243. Redston M., Nathanson K. L., Yuan Z. Q., Neuhausen S. L., Satagopan J., Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H. The APCI1307K allele and breast cancer risk. Nat Genet. 1998 Sep;20(1):13–14. doi: 10.1038/1666. [DOI] [PubMed] [Google Scholar]
  244. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997 Sep 1;57(17):3657–3659. [PubMed] [Google Scholar]
  245. Roodi N., Bailey L. R., Kao W. Y., Verrier C. S., Yee C. J., Dupont W. D., Parl F. F. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995 Mar 15;87(6):446–451. doi: 10.1093/jnci/87.6.446. [DOI] [PubMed] [Google Scholar]
  246. Rousseau-Merck M. F., Misrahi M., Loosfelt H., Milgrom E., Berger R. Localization of the human progesterone receptor gene to chromosome 11q22-q23. Hum Genet. 1987 Nov;77(3):280–282. doi: 10.1007/BF00284486. [DOI] [PubMed] [Google Scholar]
  247. Rowe S. M., Coughlan S. J., McKenna N. J., Garrett E., Kieback D. G., Carney D. N., Headon D. R. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res. 1995 Jul 1;55(13):2743–2745. [PubMed] [Google Scholar]
  248. Ruggiero M., Pacini S., Aterini S., Fallai C., Ruggiero C., Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res. 1998;10(1):43–46. [PubMed] [Google Scholar]
  249. Rundle A., Tang D., Zhou J., Cho S., Perera F. The association between glutathione S-transferase M1 genotype and polycyclic aromatic hydrocarbon-DNA adducts in breast tissue. Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1079–1085. [PubMed] [Google Scholar]
  250. Saglio G., Camaschella C., Giai M., Serra A., Guerrasio A., Peirone B., Gasparini P., Mazza U., Ceppellini R., Biglia N. Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population. Breast Cancer Res Treat. 1988 May;11(2):147–153. doi: 10.1007/BF01805838. [DOI] [PubMed] [Google Scholar]
  251. Sardaş S., Cok I., Sardaş O. S., Ilhan O., Karakaya A. E. Polymorphic N-acetylation capacity in breast cancer patients. Int J Cancer. 1990 Dec 15;46(6):1138–1139. doi: 10.1002/ijc.2910460633. [DOI] [PubMed] [Google Scholar]
  252. Sargent C. A., Dunham I., Trowsdale J., Campbell R. D. Human major histocompatibility complex contains genes for the major heat shock protein HSP70. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1968–1972. doi: 10.1073/pnas.86.6.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  253. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D. A., Smith S., Uziel T., Sfez S. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995 Jun 23;268(5218):1749–1753. doi: 10.1126/science.7792600. [DOI] [PubMed] [Google Scholar]
  254. Schechter A. L., Stern D. F., Vaidyanathan L., Decker S. J., Drebin J. A., Greene M. I., Weinberg R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984 Dec 6;312(5994):513–516. doi: 10.1038/312513a0. [DOI] [PubMed] [Google Scholar]
  255. Seidegård J., Pero R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis. 1990 Jan;11(1):33–36. doi: 10.1093/carcin/11.1.33. [DOI] [PubMed] [Google Scholar]
  256. Seidegård J., Vorachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293–7297. doi: 10.1073/pnas.85.19.7293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  257. Seitz S., Rohde K., Bender E., Nothnagel A., Kölble K., Schlag P. M., Scherneck S. Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene. 1997 Feb 13;14(6):741–743. doi: 10.1038/sj.onc.1200881. [DOI] [PubMed] [Google Scholar]
  258. Seitz S., Rohde K., Bender E., Nothnagel A., Pidde H., Ullrich O. M., El-Zehairy A., Haensch W., Jandrig B., Kölble K. Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis. Br J Cancer. 1997;76(8):983–991. doi: 10.1038/bjc.1997.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  259. Serova O. M., Mazoyer S., Puget N., Dubois V., Tonin P., Shugart Y. Y., Goldgar D., Narod S. A., Lynch H. T., Lenoir G. M. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet. 1997 Mar;60(3):486–495. [PMC free article] [PubMed] [Google Scholar]
  260. Shafman T. D., Levitz S., Nixon A. J., Gibans L. A., Nichols K. E., Bell D. W., Ishioka C., Isselbacher K. J., Gelman R., Garber J. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000 Feb;27(2):124–129. [PubMed] [Google Scholar]
  261. Sheng Z. M., Guerin M., Gabillot M., Spielmann M., Riou G. c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles. Oncogene Res. 1988 Feb;2(3):245–250. [PubMed] [Google Scholar]
  262. Shiao Y. H., Chen V. W., Scheer W. D., Wu X. C., Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995 Apr 1;55(7):1485–1490. [PubMed] [Google Scholar]
  263. Shigeta T., Takagi M., Delia D., Chessa L., Iwata S., Kanke Y., Asada M., Eguchi M., Mizutani S. Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Cancer Res. 1999 Jun 1;59(11):2602–2607. [PubMed] [Google Scholar]
  264. Sidransky D., Tokino T., Helzlsouer K., Zehnbauer B., Rausch G., Shelton B., Prestigiacomo L., Vogelstein B., Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992 May 15;52(10):2984–2986. [PubMed] [Google Scholar]
  265. Siegelmann-Danieli N., Buetow K. H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer. 1999 Feb;79(3-4):456–463. doi: 10.1038/sj.bjc.6690071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  266. Sigbjörnsdottir B. I., Ragnarsson G., Agnarsson B. A., Huiping C., Barkardottir R. B., Egilsson V., Ingvarsson S. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet. 2000 May;37(5):342–347. doi: 10.1136/jmg.37.5.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  267. Singh B., Ittmann M. M., Krolewski J. J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer. 1998 Feb;21(2):166–171. [PubMed] [Google Scholar]
  268. Själander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996 Jun;17(6):1313–1316. doi: 10.1093/carcin/17.6.1313. [DOI] [PubMed] [Google Scholar]
  269. Själander A., Birgander R., Kivelä A., Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995 May-Jun;45(3):144–149. doi: 10.1159/000154275. [DOI] [PubMed] [Google Scholar]
  270. Smith C. A., Moss J. E., Gough A. C., Spurr N. K., Wolf C. R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect. 1992 Nov;98:107–112. doi: 10.1289/ehp.9298107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  271. Smith C. M., Ma N. S., Nowak N. J., Shows T. B., Gerhard D. S. A 3-Mb contig from D11S987 to MLK3, a gene-rich region in 11q13. Genome Res. 1997 Aug;7(8):835–842. doi: 10.1101/gr.7.8.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  272. Smith E. L., Walworth N. C., Holick M. F. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986 Jun;86(6):709–714. doi: 10.1111/1523-1747.ep12276343. [DOI] [PubMed] [Google Scholar]
  273. Smith G., Stanley L. A., Sim E., Strange R. C., Wolf C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65. [PubMed] [Google Scholar]
  274. Southey M. C., Batten L. E., McCredie M. R., Giles G. G., Dite G., Hopper J. L., Venter D. J. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Natl Cancer Inst. 1998 Apr 1;90(7):532–536. doi: 10.1093/jnci/90.7.532. [DOI] [PubMed] [Google Scholar]
  275. Spurdle A. B., Dite G. S., Chen X., Mayne C. J., Southey M. C., Batten L. E., Chy H., Trute L., McCredie M. R., Giles G. G. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst. 1999 Jun 2;91(11):961–966. doi: 10.1093/jnci/91.11.961. [DOI] [PubMed] [Google Scholar]
  276. Stankovic T., Kidd A. M., Sutcliffe A., McGuire G. M., Robinson P., Weber P., Bedenham T., Bradwell A. R., Easton D. F., Lennox G. G. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998 Feb;62(2):334–345. doi: 10.1086/301706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  277. Starink T. M., van der Veen J. P., Arwert F., de Waal L. P., de Lange G. G., Gille J. J., Eriksson A. W. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986 Mar;29(3):222–233. doi: 10.1111/j.1399-0004.1986.tb00816.x. [DOI] [PubMed] [Google Scholar]
  278. Subirá M. L., Crisci C. D., Zornoza G., Sanz M. L., Voltas J., Hernández J. L., Oehling A. Breast cancer and histocompatibility antigens. Allergol Immunopathol (Madr) 1979 Nov-Dec;7(6):411–416. [PubMed] [Google Scholar]
  279. Suto R., Srivastava P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995 Sep 15;269(5230):1585–1588. doi: 10.1126/science.7545313. [DOI] [PubMed] [Google Scholar]
  280. Suzuki A., Shao X., Song X. Q., Hanaoka T., Irie S., Kashiwada M., Samara G., Close L. G., Aoki T., Fujimori M. Identification of a 5-cM region of common allelic loss on 8p12-p21 in human breast cancer and genomic analysis of the hEXT1L/EXTR1/EXTL3 gene in this locus. Int J Oncol. 1999 Sep;15(3):443–451. doi: 10.3892/ijo.15.3.443. [DOI] [PubMed] [Google Scholar]
  281. Swift M., Morrell D., Massey R. B., Chase C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991 Dec 26;325(26):1831–1836. doi: 10.1056/NEJM199112263252602. [DOI] [PubMed] [Google Scholar]
  282. Swift M., Reitnauer P. J., Morrell D., Chase C. L. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987 May 21;316(21):1289–1294. doi: 10.1056/NEJM198705213162101. [DOI] [PubMed] [Google Scholar]
  283. Sørlie T., Bukholm I., Børresen-Dale A. L. Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. Hum Mutat. 1998;12(3):215–215. [PubMed] [Google Scholar]
  284. Taioli E., Bradlow H. L., Garbers S. V., Sepkovic D. W., Osborne M. P., Trachman J., Ganguly S., Garte S. J. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev. 1999;23(3):232–237. doi: 10.1046/j.1525-1500.1999.09912.x. [DOI] [PubMed] [Google Scholar]
  285. Takasugi M., Terasaki P. I., Henderson B., Mickey M. R., Menck H., Thompson R. W. HL-A antigens in solid tumors. Cancer Res. 1973 Apr;33(4):648–650. [PubMed] [Google Scholar]
  286. Tan L., Muto N. Purification and reconstitution properties of human placental aromatase. A cytochrome P-450-type monooxygenase. Eur J Biochem. 1986 Apr 15;156(2):243–250. doi: 10.1111/j.1432-1033.1986.tb09574.x. [DOI] [PubMed] [Google Scholar]
  287. Taymans S. E., Pack S., Pak E., Orban Z., Barsony J., Zhuang Z., Stratakis C. A. The human vitamin D receptor gene (VDR) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: genetic and physical VDR map. J Bone Miner Res. 1999 Jul;14(7):1163–1166. doi: 10.1359/jbmr.1999.14.7.1163. [DOI] [PubMed] [Google Scholar]
  288. Thompson A. M., Anderson T. J., Condie A., Prosser J., Chetty U., Carter D. C., Evans H. J., Steel C. M. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer. 1992 Feb 20;50(4):528–532. doi: 10.1002/ijc.2910500405. [DOI] [PubMed] [Google Scholar]
  289. Thompson P. A., Shields P. G., Freudenheim J. L., Stone A., Vena J. E., Marshall J. R., Graham S., Laughlin R., Nemoto T., Kadlubar F. F. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 1998 May 15;58(10):2107–2110. [PubMed] [Google Scholar]
  290. Togo A. V., Suspitsin E. N., Grigoriev M. Y., Ilyushik E. S., Karpova M. B., Hanson K. P., Imyanitov E. N. L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumor-free individuals in Russia. Int J Cancer. 2000 Mar 15;85(6):747–750. doi: 10.1002/(sici)1097-0215(20000315)85:6<747::aid-ijc1>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  291. Topić E., Stefanović M., Ivanisević A. M., Petrinović R., Curcić I. The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients. Clin Chim Acta. 2000 Jun;296(1-2):101–109. doi: 10.1016/s0009-8981(00)00221-7. [DOI] [PubMed] [Google Scholar]
  292. Tsou H. C., Teng D. H., Ping X. L., Brancolini V., Davis T., Hu R., Xie X. X., Gruener A. C., Schrager C. A., Christiano A. M. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997 Nov;61(5):1036–1043. doi: 10.1086/301607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  293. Ueda K., Nishijima M., Inui H., Watatani M., Yayoi E., Okamura J., Yasutomi M., Nakamura Y., Miyoshi Y. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res. 1998 Jan;89(1):17–21. doi: 10.1111/j.1349-7006.1998.tb00473.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  294. Venitt S. Mechanisms of carcinogenesis and individual susceptibility to cancer. Clin Chem. 1994 Jul;40(7 Pt 2):1421–1425. [PubMed] [Google Scholar]
  295. Vineis P., Caporaso N. The analysis of restriction fragment length polymorphism in human cancer: a review from an epidemiological perspective. Int J Cancer. 1991 Jan 2;47(1):26–30. doi: 10.1002/ijc.2910470106. [DOI] [PubMed] [Google Scholar]
  296. Vorechovský I., Luo L., Lindblom A., Negrini M., Webster A. D., Croce C. M., Hammarström L. ATM mutations in cancer families. Cancer Res. 1996 Sep 15;56(18):4130–4133. [PubMed] [Google Scholar]
  297. Vorechovský I., Rasio D., Luo L., Monaco C., Hammarström L., Webster A. D., Zaloudik J., Barbanti-Brodani G., James M., Russo G. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res. 1996 Jun 15;56(12):2726–2732. [PubMed] [Google Scholar]
  298. Wang-Gohrke S., Chang-Claude J., Becher H., Kieback D. G., Runnebaum I. B. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res. 2000 May 1;60(9):2348–2350. [PubMed] [Google Scholar]
  299. Wang-Gohrke S., Rebbeck T. R., Besenfelder W., Kreienberg R., Runnebaum I. B. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 1998 May-Jun;18(3B):2095–2099. [PubMed] [Google Scholar]
  300. Wang J. C., Radford D. M., Holt M. S., Helms C., Goate A., Brandt W., Parik M., Phillips N. J., DeSchryver K., Schuh M. E. Sequence-ready contig for the 1.4-cM ductal carcinoma in situ loss of heterozygosity region on chromosome 8p22-p23. Genomics. 1999 Aug 15;60(1):1–11. doi: 10.1006/geno.1999.5905. [DOI] [PubMed] [Google Scholar]
  301. Watanabe J., Harada N., Suemasu K., Higashi Y., Gotoh O., Kawajiri K. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics. 1997 Oct;7(5):419–424. doi: 10.1097/00008571-199710000-00014. [DOI] [PubMed] [Google Scholar]
  302. Watanabe J., Shimada T., Gillam E. M., Ikuta T., Suemasu K., Higashi Y., Gotoh O., Kawajiri K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 2000 Feb;10(1):25–33. doi: 10.1097/00008571-200002000-00004. [DOI] [PubMed] [Google Scholar]
  303. Weber B. L., Nathanson K. L. Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 2000 Jun;36(10):1193–1199. doi: 10.1016/s0959-8049(00)00082-4. [DOI] [PubMed] [Google Scholar]
  304. Webster D. J., Flook D., Jenkins J., Hutchings A., Routledge P. A. Drug acetylation in breast cancer. Br J Cancer. 1989 Aug;60(2):236–237. doi: 10.1038/bjc.1989.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  305. Weinberg E. D. The role of iron in cancer. Eur J Cancer Prev. 1996 Feb;5(1):19–36. [PubMed] [Google Scholar]
  306. Weisz J., Fritz-Wolz G., Gestl S., Clawson G. A., Creveling C. R., Liehr J. G., Dabbs D. Nuclear localization of catechol-O-methyltransferase in neoplastic and nonneoplastic mammary epithelial cells. Am J Pathol. 2000 Jun;156(6):1841–1848. doi: 10.1016/S0002-9440(10)65057-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  307. Weston A., Pan C. F., Bleiweiss I. J., Ksieski H. B., Roy N., Maloney N., Wolff M. S. CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):941–944. [PubMed] [Google Scholar]
  308. Weston A., Pan C. F., Ksieski H. B., Wallenstein S., Berkowitz G. S., Tartter P. I., Bleiweiss I. J., Brower S. T., Senie R. T., Wolff M. S. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):105–112. [PubMed] [Google Scholar]
  309. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246–5250. doi: 10.1073/pnas.95.9.5246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  310. Wiencke J. K., Pemble S., Ketterer B., Kelsey K. T. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):253–259. [PubMed] [Google Scholar]
  311. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O., Duff G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  312. Wilson A. G., de Vries N., Pociot F., di Giovine F. S., van der Putte L. B., Duff G. W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993 Feb 1;177(2):557–560. doi: 10.1084/jem.177.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  313. Winqvist R., Lundström K., Salminen M., Laatikainen M., Ulmanen I. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet Cell Genet. 1992;59(4):253–257. doi: 10.1159/000133262. [DOI] [PubMed] [Google Scholar]
  314. Winqvist R., Peltoketo H., Isomaa V., Grzeschik K. H., Mannermaa A., Vihko R. The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with ScaI. Hum Genet. 1990 Oct;85(5):473–476. doi: 10.1007/BF00194219. [DOI] [PubMed] [Google Scholar]
  315. Woodage T., King S. M., Wacholder S., Hartge P., Struewing J. P., McAdams M., Laken S. J., Tucker M. A., Brody L. C. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet. 1998 Sep;20(1):62–65. doi: 10.1038/1722. [DOI] [PubMed] [Google Scholar]
  316. Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., Barrett-Lee P., Easton D. F., Ponder B. A., Stratton M. R. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet. 1992 Oct;2(2):132–134. doi: 10.1038/ng1092-132. [DOI] [PubMed] [Google Scholar]
  317. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. doi: 10.1126/science.8091231. [DOI] [PubMed] [Google Scholar]
  318. Wundrack I., Sasiadek M., Blin N. Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1. Anticancer Res. 1997 Nov-Dec;17(6D):4515–4517. [PubMed] [Google Scholar]
  319. Xie D., Shu X. O., Deng Z., Wen W. Q., Creek K. E., Dai Q., Gao Y. T., Jin F., Zheng W. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000 Mar 1;92(5):412–417. doi: 10.1093/jnci/92.5.412. [DOI] [PubMed] [Google Scholar]
  320. Yaremko M. L., Kutza C., Lyzak J., Mick R., Recant W. M., Westbrook C. A. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer. 1996 Jul;16(3):189–195. doi: 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  321. Yaremko M. L., Recant W. M., Westbrook C. A. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer. 1995 Jul;13(3):186–191. doi: 10.1002/gcc.2870130308. [DOI] [PubMed] [Google Scholar]
  322. Yokota T., Yoshimoto M., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y., Emi M. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1. Cancer. 1999 Jan 15;85(2):447–452. [PubMed] [Google Scholar]
  323. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991 Jul 25;352(6333):345–347. doi: 10.1038/352345a0. [DOI] [PubMed] [Google Scholar]
  324. Young I. E., Kurian K. M., Annink C., Kunkler I. H., Anderson V. A., Cohen B. B., Hooper M. L., Wyllie A. H., Steel C. M. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer. 1999 Sep;81(1):141–143. doi: 10.1038/sj.bjc.6690663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  325. Young R. A. Stress proteins and immunology. Annu Rev Immunol. 1990;8:401–420. doi: 10.1146/annurev.iy.08.040190.002153. [DOI] [PubMed] [Google Scholar]
  326. Yu C. E., Oshima J., Fu Y. H., Wijsman E. M., Hisama F., Alisch R., Matthews S., Nakura J., Miki T., Ouais S. Positional cloning of the Werner's syndrome gene. Science. 1996 Apr 12;272(5259):258–262. doi: 10.1126/science.272.5259.258. [DOI] [PubMed] [Google Scholar]
  327. Zheng W., Deitz A. C., Campbell D. R., Wen W. Q., Cerhan J. R., Sellers T. A., Folsom A. R., Hein D. W. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):233–239. [PubMed] [Google Scholar]
  328. Zheng W., Xie D. W., Jin F., Cheng J. R., Dai Q., Wen W. Q., Shu X. O., Gao Y. T. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):147–150. [PubMed] [Google Scholar]
  329. Zhong S., Wyllie A. H., Barnes D., Wolf C. R., Spurr N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis. 1993 Sep;14(9):1821–1824. doi: 10.1093/carcin/14.9.1821. [DOI] [PubMed] [Google Scholar]
  330. Zhu B. T., Conney A. H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 1998 Jun 1;58(11):2269–2277. [PubMed] [Google Scholar]
  331. Zimniak P., Nanduri B., Pikuła S., Bandorowicz-Pikuła J., Singhal S. S., Srivastava S. K., Awasthi S., Awasthi Y. C. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994 Sep 15;224(3):893–899. doi: 10.1111/j.1432-1033.1994.00893.x. [DOI] [PubMed] [Google Scholar]
  332. Zuppan P., Hall J. M., Lee M. K., Ponglikitmongkol M., King M. C. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet. 1991 Jun;48(6):1065–1068. [PMC free article] [PubMed] [Google Scholar]
  333. de Jong-Bakker M., Cleton F. J., D'Amaro J., Keuning J. J., Van Rood J. J. HL-A antigens and breast cancer. Eur J Cancer. 1974 Sep;10(9):555–558. doi: 10.1016/0014-2964(74)90041-3. [DOI] [PubMed] [Google Scholar]
  334. te Meerman G. J., de Vries E. G. Relevance of high and low penetrance. Lancet. 2001 Jul 28;358(9278):331–332. doi: 10.1016/S0140-6736(01)05506-4. [DOI] [PubMed] [Google Scholar]
  335. van Es H. H., Bout A., Liu J., Anderson L., Duncan A. M., Bosma P., Oude Elferink R., Jansen P. L., Chowdhury J. R., Schurr E. Assignment of the human UDP glucuronosyltransferase gene (UGT1A1) to chromosome region 2q37. Cytogenet Cell Genet. 1993;63(2):114–116. doi: 10.1159/000133513. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES